Age: 53.0
Sex: F
Vaccine: COVID19, UNK
Symptoms: Back pain, Loss of personal independence in daily activities, Memory impairment, Peripheral venous disease, Post procedural contusion
Clinical narrative: Intraoperative venous injury; Memory impaired; Dental disorder NOS; back pain; Loss of personal independence in daily activities; Postoperative bruise; Procedural site pain; Postoperative thrombosis; Venous peripheral insufficiency; This is a Solicited report from a non-contactable consumer (patient) based on the information received by Pfizer from AbbVie (MFR Control No: 21K-163-3951457-00).   A 53-year-old female patient received bnt162b2 (BNT162B2), dose 1 intramuscular on 17Mar2021 (Lot Number: EN6208) as single dose, dose 2 intramuscular on 07Apr2021 (Lot Number: AW0151) as single dose for covid-19 immunisation; adalimumab (HUMIRA), subcutaneous from an unspecified date to an unspecified date, at UNK, Discontinued, subcutaneous from unknown date (reported as 10Jul2021 which is a future date) to an unspecified date, at 0.4 mL, weekly(40mg, weekly) for Moderate to severe Hidradenitis suppurativa and Moderate to severe Rheumatoid arthritis.   Medical history included abstains from alcohol, leg surgery, fibromyalgia, high cholesterol, penicillin allergy manifested by hives, smoker (smoker-ten sticks of cigarettes per day). Concomitant medications included paracetamol (TYLENOL); montelukast (MONTELUKAST); omeprazole (OMEPRAZOLE); vitamin d3 (VITAMIN D3); loratadine (LORATADINE); folic acid (FOLIC ACID); pregabalin (LYRICA); fluticasone propionate, salmeterol xinafoate (ADVAIR); methotrexate (METHOTREXATE); ibuprofen (MOTRIN CHILDREN); salbutamol (ALBUTEROL HFA).   The patient experienced postoperative thrombosis on 06Apr2021 with outcome of not recovered , venous peripheral insufficiency on 06Apr2021 with outcome of not recovered , venous operation on an unspecified date with outcome of not recovered, procedural site pain on May2021 with outcome of recovering, intraoperative venous injury on an unspecified date with outcome of not recovered , postoperative bruise on May2021 with outcome of recovered in 2021, memory impaired on an unspecified date with outcome of not recovered , dental disorder nos on an unspecified date with outcome of not recovered , back pain on an unspecified date with outcome of unknown , loss of personal independence in daily activities on an unspecified date with outcome of unknown.  The patient underwent lab tests and procedures which included ultrasound: Insufficient Vein on May2021.  The action taken in response to the event for bnt162b2 was not applicable, for adalimumab was unknown.  The reporter's assessment of the causal relationship of the events with the suspect product was not provided at the time of this report. Since no determination has been received, the case is managed based on the company causality assessment.  No follow-up attempts are possible. No further information is expected.; Sender's Comments: There is no reasonable possibility that reported events Postoperative thrombosis, Venous peripheral insufficiency, Procedural site pain, Intraoperative venous injury, Postoperative bruise, Memory impaired, dental disorder, back pain and loss of personal independence are related to BNT162B2. The events are likely intercurrent conditions.